Novartis is paying up to $900 million to license an experimental radioligand therapy from BoomRay Pharmaceuticals, a China-based biotech — a deal that both deepens Novartis’s dominance in targeted radioactive cancer treatment and adds to a fast-growing wave of Western pharma buying innovation from China.
What’s being bought
The two companies signed an exclusive worldwide license for an undisclosed preclinical radioligand therapy (RLT) asset, valued at up to $900 million. The terms follow the standard biotech template: an undisclosed upfront payment, plus development, regulatory and sales milestones and royalties on future global sales.
What radioligand therapy is
Radioligand therapies are targeted radioactive drugs: a homing molecule seeks out a marker on cancer cells and delivers a payload of radiation directly to the tumor, limiting damage to healthy tissue. It’s one of oncology’s most promising frontiers — and Novartis is already a leader, with approved radioligand products on the market. BoomRay, for its part, brings an integrated platform spanning candidate discovery, radiochemistry and clinical translation — the specialized capabilities this complex field demands.
Why Novartis keeps buying in this space
This is not a one-off. It follows Novartis’s May 2024 acquisition of Mariana Oncology for $1 billion upfront plus up to $750 million in milestones, part of a sustained, aggressive push into radiopharmaceuticals. “Radioligand therapies represent an important frontier in oncology,” said Novartis oncology research head Shiva Malek, adding that the BoomRay asset complements Novartis’s existing radioligand portfolio. The strategy is to own more of a scarce, fast-growing field — a theme echoed across the sector, where rivals are also racing to lock up assets and isotope supply.
The China angle
Equally notable is where the asset comes from. Licensing a promising drug from a Chinese biotech fits a broader, accelerating trend: Chinese companies have become prolific, cost-effective sources of novel drug candidates, and Western pharma is increasingly shopping there. It’s part of the same story reflected in European leaders’ anxieties about losing ground — China’s biopharma innovation is reshaping global dealmaking.
Why it matters — and the caveat
For patients, more investment in radioligand therapy could eventually mean more targeted options for hard-to-treat cancers. For the industry, the deal is another marker of radiopharma’s rise and of China’s growing role as an innovation engine. The caveats are standard: the asset is preclinical, so it’s years and many hurdles away from patients, and the $900 million is a ceiling tied to milestones, not a guaranteed payout. Business news, not investment advice.